Deadline Approaching for ImmunityBio Investors to Lead Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces opportunity for investors with substantial losses to serve as lead plaintiff

Apr. 6, 2026 at 11:37am

Got story updates? Submit your updates here. ›

Robbins Geller Rudman & Dowd LLP has announced that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026 have until May 26, 2026 to seek appointment as lead plaintiff in a class action lawsuit against the company and its Executive Chairman. The lawsuit alleges that ImmunityBio made false and misleading statements about its lead biologics product, Anktiva.

Why it matters

This lawsuit represents an opportunity for ImmunityBio investors who suffered substantial losses during the class period to potentially recoup those losses by serving as the lead plaintiff in the case. The outcome of the lawsuit could also have broader implications for how biotechnology companies market and promote their products.

The details

The class action lawsuit, captioned Douglas v. ImmunityBio, Inc., No. 26-cv-03261 (C.D. Cal.), alleges that ImmunityBio and its Executive Chairman, Dr. Patrick Soon-Shion, made false and misleading statements about Anktiva, the company's lead biologics product. Specifically, the lawsuit claims that defendants falsely represented that Anktiva would allow all non-muscle invasive bladder cancer (NMIBC) patients treated with it to be cancer-free long-term, and that Anktiva is a cancer vaccine, when these claims were not demonstrated. The lawsuit further alleges that Dr. Soon-Shion materially overstated Anktiva's capabilities.

  • The class period for the lawsuit is January 19, 2026 to March 24, 2026, inclusive.
  • Investors have until May 26, 2026 to seek appointment as lead plaintiff.

The players

ImmunityBio, Inc.

A biotechnology company that focuses on innovating, developing, and commercializing next-generation immunotherapies. Its lead biologics product is Anktiva.

Dr. Patrick Soon-Shion

ImmunityBio's Executive Chairman and Global Scientific and Medical Officer, who is alleged to have materially overstated Anktiva's capabilities.

Richard Adcock

The CEO of ImmunityBio.

Robbins Geller Rudman & Dowd LLP

A law firm representing investors in the class action lawsuit against ImmunityBio.

U.S. Food and Drug Administration (FDA)

The federal agency that issued a warning letter to ImmunityBio regarding misleading promotional communications about Anktiva.

Got photos? Submit your photos here. ›

What’s next

Investors with substantial losses have until May 26, 2026 to seek appointment as lead plaintiff in the class action lawsuit against ImmunityBio.

The takeaway

This lawsuit highlights the importance of biotechnology companies accurately representing the capabilities of their products in promotional materials. Investors who suffered losses due to allegedly misleading claims about Anktiva have an opportunity to seek recourse through the class action lawsuit.